Drugs / MDG1015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06748872 | Jul 2025 → Dec 2027 expected | gastroesophageal cancer, malignant epithelial tumor of ovary, myxoid liposarcoma, synovial sarcoma | MediGene | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDG1015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06748872 ↗ |
| Modality | Cell therapy | “MDG1015 is a third generation TCR-T therapy product” NCT06748872 ↗ |